Position in ATAI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,370,137
-$2,571,090 QoQ
Shares Held
2,364,446
-11.6% QoQ
Ownership
0.642%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ATAI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MARSHALL WACE, LLP holds $2,764,425,276 across 279 Biotechnology names. ATAI ranks #68 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,099,318 | $363,731,344 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
317,058 | $141,579,078 | |
| 3 | INCY |
Incyte Corp
|
1,253,138 | $117,945,347 | |
| 4 | RPRX |
Royalty Pharma plc
|
2,120,692 | $101,729,594 | |
| 5 | RCUS |
Arcus Biosciences, Inc.
|
3,761,437 | $81,247,039 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
628,075 | $66,199,104 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
2,246,943 | $62,240,320 | |
| 8 | COGT |
Cogent Biosciences, Inc.
|
1,600,168 | $61,590,466 |
All Filings in ATAI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,370,137 | 2,364,446 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $10,941,227 | 2,675,117 | Shares | Other | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||